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Douglas A. Clpkala, William H. Livingston, Robert E. Kelley, Robert J. Cody. Ohio
State University, Columbus, OH
Constitutive protein mRNA is utilized as an index for target protein mRNA
expression in experimental models. It is assumed that constitutive protein
mRNA expression is not altered by disease states or pharmacologic interven-
tion. We evaluated whether pressure overload, or long term angiotensin con-
verting enzyme (ACE) inhibition, would alter the expression of two constitu-
tive protein mRNA:s: cyclophilin and G3PDH. 16 wk spontaneously hyperten-
sive rats (SHR) were treated with enalapril (10 mglkg; n = 9). or placebo (n =
15). for 12 wks, compared to Wistar Kyoto normal controls (n = 18). Terminal
hemodynamics were performed following therapy, with aortic flow (mean:
MAF, mlfmin). pressure (mean: MAp, mmHg), and heart rate (HR, bpm). Sys-
temic arterial resistance (SAR, units) was derived from digitized waveforms.
Myocardial function was assessed by left ventricular end diastolic pressure
(LVEDP, mmHg), and contractility (+dp/dt). Hemodynamics were followed by
harvest of left ventricle (LV). and kidney (K) tissue, which were stored at _80'
C. Total RNA was extracted, and dot blot analysis of cyclophilin and G3PDH
mRNA was performed. Each probe mRNA was quantified by densitometry,
and expressed as a relative density ratio of cyclophilin/G3PDH (C/G). Renal
tissue ACE levels (activity units) were utilized to document ACE inhibition,
and were 2.5 ± 1.3 (normal). 1.8 ± 0.8 (placebo SHR). and 1.0 ± 0.3 (enalapril
SHR, p = 0.05, compared to placebo). Analysis of variance was performed
and mean values are as given below:
Influence of Pressure Overload and ACE
Inhibitor Therapy on Constitutive Protein mRNA
Expression In the Spontaneously Hypertensive
Rat
t P < 0.05: placebo vs enalapril
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Prognosis of Patients with Symptomatic Heart
Failure (HF) Considered Too Well for Cardiac
Transplantation (Htx): Predictors of Adverse
Outcome
Peter R. Rickenbacher, Pedro T. Trindade. Guy A. Haywood. Randall H. Vagelos,
John S. Schroeder, Kathy Willson. Lisa Prikaszky. Michael B. Fowler. Stanford
University, Stanford, California
Donor organ shortage demands limiting the selection of candidates for Htx
to patients (pts) with the worst prognosis. Current pharmacological treat-
ment strategies for HF have been shown to improve survival. The purpose
of this study was to assess the prognosis of pts with symptomatic HF con-
sidered too well for Htx and to identify predictors of an adverse outcome.
Of 645 consecutive pts referred for Htx evaluation, 116 (age 46.6 ± 10.3
years, 24% females) with symptomatic HF and an ejection fraction of ~35%
(mean, 20 ± 7%) were considered too well for the procedure and formed the
study population. During a mean follow-up of 25.0 ± 14.8 months (follow-
up 99% complete), 8 (7%) cardiac deaths (7 sudden) occurred and 9 pts
(8%) required listing for Htx. Actuarial 1- and 4-year cardiac survival was 9B
± 1% and 84 ± 7% and freedom from listing for Htx was 95 ± 2% and
84 ± 7% respectively. By multivariate regression analysis inclUding base-
line clinical, hemodynamic and exercise variables, only a history of sustained
VT/aborted SCD (VTISCD) was an independent predictor of cardiac death (p
< 0.03) and longer duration of HF symptoms predicted the need for later Htx
(p = 0.004). Actuarial survival curves for patients with vs without history of
VT/SCD and with HF symptoms for> 12 months vs ~12 months are shown
below:
11031-311
C/G-K
1.60
138
1.52
C/G-LV
1.43
1.78
1.73
+DP/DT
16812t
8933
12341
LVEDP
9.4t
2.3
1.7
1.47t
0.67
0.46
SARMAF
loot
145
181
MAP
149t
92
80
HR
410
407
299
Placebo SHR
Enalapril SHR
Normal
11030-14 1
[ 1030-15 1
Conclusion: In the current treatment era, prognosis is favorable in carefully
selected pts considered too well for Htx despite symptomatic heart failure.
A history of VT/SCD helps in identifying a subgroup at risk for sudden car-
diac death. Close observation of pts with longer duration of HF allows timely
referral for Htx if hemodynamic deterioration occurs.
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Felodipine Versus Enalapril in Heart Failure:
Results on Peak Oxygen Consumption, Holter
Recordings Hemodynamics, Neurohormones,
and Quality of Life
Rob J. de Vries 1, Michel Ouere, Dirk J. LOk, Pieter Sijbring, Jeroen J. Bucx, Peter
H. Dunselman. Working Group on Cardiovascular Research, Breda, The Netherlands;
1 Thoraxcenter, UniverSity Hospital Groningen, The Netherlands
Felodipine (FEL) is a vasoselective dihydropyridine calcium antagonist that
has shown promising results in smaller congestive heart failure (CHF) stud-
ies. Angiotensin converting enzyme inhibitors (ACEI) are the cornerstone of
CHF therapy, but many patients can not be treated with these drugs because
of side effects or contraindications. We compared the effects of FEL. 10 mg
b.Ld" and enalapril (ENA), 10 mg b.Ld., in a double blind, parallel study in
50 patients with CHF. At baseline and after 16 weeks treatment cardiopul-
monary exercise test. neurohormone sampling, Holter recording and quality
of life questionaires were assessed.
Patients: Fifty patients with CHF, NYHA class II-III, mean age 64 ± 7 yr.,
mean LVEF of 26 ± 9%, mean peak oxygen consumption of 14.8 ± 3.5
ml/minlkg. mean norepinephrine 683 ± 470 pg/ml and mean plasma renin
activity of 0.9 ± 0.8 ng/mllhr were randomized, after a 2 week placebo pe-
riod, to FEL and ENA.
Results: Exercise duration was increased 63 sec and peak oxygen con-
sumption 0.7 mllkg/min after FEL, and 60 sec and 1.4 mllkg/min after ENA
(P = NS). Rate pressure product (RPP) at peak exercise was significantly low-
ered by Fel (p < 0.005). Plasma norepinephrine decreased after both Fel and
ENA by 46 and 150 pg/ml respectively, whereas plasma renin increased by
0.7 and 4.1 ng/ml/hr respectively (both P = NS). FEL patients significantly
better results on quality of life score. Holter recordings revealed no proar-
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Endothelln-1 Modulates Conduit Vessel
Compliance as Well as Peripheral Vascular
Tone: Implications for Endotheiin Mediated
Regulation of Blood Pressure
Philip F. Binkley, Douglas Brown, Robert J. Cody. The Ohio State University,
Columbus, OH
Thus, severe pressure overload does not alter LV and K cyclophilin and
G3PDH mRNA expression in the SHR, although age-dependent changes of
mRNA expression were not evaluated in this study. Furthermore, long term
ACE inhibition did not alter their expression in a systematic manner.
Although the endothelins have well recognized effects on peripheral vascu-
lar resistance, their capacity to modulate conduit vessel tone in vivo remains
incompletely defined. Therefore, characteristic impedance of the aorta was
derived from measurement of central aortic pressure and flow in 6 normoten-
sive rats at baseline and following bolus infusion of endothelin-l , the most
potent peripheral vasoconstrictor of the endothelin peptides. Endothelin-l
produced a typical biphasic peripheral vascular response with an initial de-
crease in systemic vascular resistance (svr) (dynes-sec/cm5) from 2.1 x 105
± 0.5 x 105 to 0.5 x 105 ± 1. x 105 followed by a significant (p = 0.05) in-
crease over baseline to 2.6 x 105 ± 0.8 x 105. A significant (p = 0.02) change
in characteristic impedance of the aorta (dynes-sec/cmS) was observed with
an increase over the baseline value of 6.6 x 103 ± 2.2 x 103 to 8.1 x 103 ±
2.9 x 103: which occurred immediately following bolus infusion and during
the nadir ,n svr, followed by a return towards the baseline value (6.6 x 103
± 2.1 x 103 during the peak increase in svr). These in vivo data indicate that
significant changes in conduit vessel tone, in addition to peripheral vascu-
lar resistance, accompany administration of endothelin-l with a significant
decrease in conduit vessel compliance, reflected by increased characteris-
tic impedance, which precedes an increase in svr. Therefore, endothelin-l
modulation of systemic blood pressure may be mediated by regulation of
conduit vessel compliance as well as peripheral vascular tone.
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rhytmias with either drug. Side effects were minor with both drugs.
Discussion: The vasoselective calcium antagonist FEL demonstrated equal
efficacy in exercise parameters, and was somewhat superior in quality of life
parameters, if compared to ENA. The massive vasodilation induced by FEL,
as demonstrated by the RPP was not accompanied by an activation of the
neurohormonal system, so often observed with other vasodilating agents.
Conclusion: FEL can be seriously considered as an alternative treatment
for ACEI in CHF patients. A direct comparison between FEL and ACEI in CHF,
with special emphasis on long term efficacy and mortality seems of interest.
Placebo Bisoprolol p
10th perc (ms) 58± 18 64 ± 30 NS
25th perc (ms) 95± 35 101 ± 35 NS
50th perc Ims) 133 ± 43 152 ± 37 0.02
75th perc Ims) 134 ± 53 171 ± 53 0004
90th perc Ims) 120± 12 139 ± 46 005
In conclusion, HRV is not improved at higher heart rates. On the contrary,
these results indicate that low dose Bisoprolol improves short term HRV at
lower heart rates in CHF
Results of Coronary Artery Bypass Grafting in
Patients with Chronic Congestive Heart Failure:
A Ten-year Experience with 203 Patients
Bal~zs M Szab6, Dirk J. van Veldhuisen, Pieter H. van der Burgh 1,Joost Kruik I,
K.1. Lie. Thoraxcenter. University Hospital Groningen, The Netherlands; 1Dept. of
Cardiology, Medisch Spectrum Twente, The Netherlands
Multiple drug therapy, including ACE inhibitors, diuretics, vasodilators and
digoxin is currently used to reduce signs and symptoms of chronic heart fail-
ure (CHF). Optimal treatment of these patients (pts) is a major clinical prob-
lem, as the prevalence of CHF increases. Ibopamine, a novel oral dopamine
agonist with peripheral vasodilating and neurohumoral inhibiting effects,
may have additive value in the treatment of pts with moderately severe CHF,
already treated with ACE-inhibitors.
To evaluate the additive value of ibopamine as adjunctive to maximal CHF
treatment we studied 60 pts with NYHA class III-IV CHF, who were assigned
to treatment with ibopamine (3 dd 100 mgl or placebo in a double-blind,
randomized fashion.
We examined the effect of ibopamine on peak oxygen consumption (V02),
neurohumoral factors and cardiac arrhythmias during 48 hrs ECG monitoring.
Neurohumoral parameters were determined at rest and during exercise and
included serum norepinephrine, epinephrine, aldosterone and plasma renin
activity. All assessments were made at baseline and after 12 weeks of study
treatment.
Baseline data: Of the 60 pts, 40 pts (67%) had ischemic heart disease
andlor old myocardial infarction, and 20 (33%) non-ischemic heart disease
(16 pts (27%) dilated myocardiopathy). Mean age was 63 ± 10 years, left
ventricular ejection fraction 0.23 ± 0.08, peak V02 15.0 ± 2.4 mllminlkg and
44 of the patients (73%) were male. Background CHF therapy included ACE-
inhibitors (100%), diuretics (100%), and digoxin, nitrates, amiodarone when
required. At baseline resting serum norepinephrine was 724 ± 78 pglml,
epinephrine 68 ± 17 pglml, aldosterone 0.50 ± 0.08 nmolll and plasma renin
aClivity 5.7 ± 0.9 ng/mllhr.
Results: The study was recently completed, the study data are currently
analyzed and the results will be presented at the meeting.
Value of lbopamine as Adjunct to Maximal Oral
Medication in Patients with Moderately Severe
Congestive Heart Failure; a Double-Blind,
Placebo-controlled Study
William A. Anderson, Deborah A. IIkowski, Javier Fernandez, Glenn W. Laub, Mark
S. Adkins, Chao Chen, Lynn B. McGrath. Deborah Heart and Lung Center, Browns
Mil/s,NJ
From 1983 to 1992,203 patients with preoperative symptoms of chronic CHF
and not angina underwent primary CABG for ischemic cardiomyopathy. This
represented 3% of all patients undergoing CABG, however, this figure rose
to 8% over the last two years of the study. Patients with valvular lesions,
left ventricular aneurysms or those with acute post infarction heart failure
were excluded. The mean age was 67 years and 63% of the patients were
male. 92% of the patients were in NYHA Class III or IV prior to undergo-
ing CABG. The mean preoperative ejection fraction was 34% ± 13% and the
mean LVEDPwas 20.7 mmHg ± 8.4 mmHg. A LIMA graft was used in 68% of
the patients. Follow-up was 98% complete. The hospital mortality was 6.0%
and the actuarial survival at 5 years was 59%. An improvement in NYHA class
occurred in 75% of the surviving patients with a mean improvement of 1.6
± 0.6 NYHA classes; 18% of the survivors remained the same and 7% were
worse. Univariate analysis identified risk factors for hospital death as emer-
gency operation, recent myocardial infarction «30 days), the need for IABP
and non use of a LIMA graft. Use of the LIMA did predict late survival (p ~
0.02), however did not affect NYHA class in the surviving patients. We con-
clude that CABG is effective in ameliorating symptoms of chronic congestive
heart failure in patients suffering from chronic ischemic cardiomyopathy and
can be performed with acceptable early and late mortality.
In~: RR
75
Intravenous Triiodothyronine in Patients with
Advanced Heart Failure
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Xavier Copie, Jean-Yves Le Heuzey, Philippe Lechat, Jean-Pierre Boissel,
Fran,ois Pousset, Fred/"ic Fillette, Willem Remme, Martin Hetzel, Louis Guize,
Patrice Jaillon, CIBIS Investigators. Broussais Hospital, Paris, France
Patients with congestive heart failure (CHF) have reduced heart rate variability
(HRV). Beta-blockers (BB) therapy could improve HRV in CHF However, HRV
is influenced by heart rate. The aim of our study was to assess the effect of
BB on heart rate adjusted-HRV in 52 patients from the randomized, double-
blind, placebo-controlled CIBIS trial (Cardiac Insufficiency Bisoprolol Study).
After progressive increase, Bisoprolol was 5 mg once a day. Holter tapes
were recorded at baseline and after 2 months of therapy. To assess HRV at
given heart rates, we developed a geometrical analysis of scatterplots (SCP).
SCP display beat-ta-beat HRV by plotting each RR against the preceding RR
interval. SCP heigth, a measure of short term HRV, was measured at the
10th, 25th, 50th, 75th and 90th percentiles of the total RR dispersion (figure).
The 10th percentile represents the fastest hearts rates, whereas the 90th
represents the slowest heart rates. There was no significant difference in
baseline SCP measurements. Results of BB therapy on SCP heights are as
follow (mean ± SD):
Michele A. Hamilton, Lynne W. Stevenson, Gregg C. Fonarow, Anthony E. Steimle,
Jaime D. Moriguchi, Antoine Hage, Michael Gleason, Susan M. Kaiser, Kim
A. Scheibly, Julie A. Walden. UClA Medical Center. Los Angdes, CA
Thyroid hormone metabolism is frequently abnormal in patients with ad-
vanced congestive heart failure (CHF), with low triiodothyronine (13) levels
associated with poor hemodynamics and increased mortality. Studies have
suggested that intravenous (Lv.) T3 improves hemodynamics acutely in pa-
tients immediately post-bypass surgery. To assess the safety of i.v. 13 (which
may have unique inotropic mechanisms) in CHF, 22 patients with class III or
IV CHF were given an Lv. 13 bolus ±6 hour infusion (total dose range 0.05
- 1.7 /.<glkg) under hemodynamic and ECG monitoring. Basal metabolic rate
(BMR) by indirect calorimetry and LVEF by echo were measured at baseline
and 2-4 hours post dosing.
Results: No patient had angina or sustained supraventricular or ventricular
ectopy and mean heart rate (HR) did not change significantly (94 ± 16 to 98 ±
13 bpm, p = NS), with only 3/22 patients having an increase in HR > 10 bpm.
There was no significant change in mean BMR (2221 ± 899 to 2449 ± 682
Kcal/day, p = NS) and only minimal change in mean core temperature (36.8
± 0.4 to 37.3 ± 0.6°C, P = 0.007), reflecting a peak temperature 38.0-38.5°
C in 4 patients. Cardiac output increased by > 1.0 Umm in 11/22 patients
(>50% increase over baseline in 8/22 patients) with no significant change in
LVEF (22 ± 7 to 23 ± 6%, P = NS) or filling pressures.
Conclusion: Acute intravenous T3 administration is well tolerated in pa-
tients with advanced CHF and has potential hemodynamic benefit warrant-
ing further investigation.
20(H~~,.- . ,-' ~T" ._,- •• , - -- ,-
200 4(XI (,(1(/ SCII 10(1'1 n", 1100 V-'l'l
Differential Effect of Bisoprolol on Heart Rate
Variability According to Heart Rate In Patients
with Heart Failure
